Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study

This observational study is tracking real-world outcomes for people in Greece with relapsing multiple sclerosis (MS) who have recently started a drug called ofatumumab (Kesimpta), with a focus on brain MRI changes and clinical improvements over time. **You may be eligible if...** - You have been diagnosed with relapsing multiple sclerosis per established criteria - You had your first MS symptoms less than 5 years ago - You have been taking ofatumumab for at least 3 months but no more than 6 months before joining the study - You have had a brain MRI at least 3 months after starting ofatumumab, or your doctor plans to perform one **You may NOT be eligible if...** - You have been on ofatumumab for less than 3 months or more than 6 months - You are unable to provide written informed consent - You do not meet the product labeling requirements for ofatumumab use Talk to your doctor to see if this trial is right for you.